PositiveSide.ca | LivePositive.ca | TreatHIVGlobally.ca | Resources for Nurses

Living with HIV

For service providers

For health care providers

Access our services

Find organizations

News and events

CATIE Ordering Centre

FRAN�AIS PREVIOUS PAGE NEXT PAGE TELL A FRIEND SUBSCRIBE

TreatmentUpdate

TreatmentUpdate is CATIE's flagship treatment digest on cutting-edge developments in HIV/AIDS research and treatment. ( 8 issues per year.)

Expand list of issues | Collapse list of issues

TU 169 2008 August/September PDF

     I ANTI-HIV AGENTS: A. Good news for HAART users NEW

     II ANTI-CANCER AGENTS: A. Kaposi’s sarcoma—past and future NEW

     II ANTI-CANCER AGENTS: B. More about KS NEW

     II ANTI-CANCER AGENTS: C. KS in HIV negative men NEW

     II ANTI-CANCER AGENTS: D. Liposomal chemo for KS NEW

TU 168 2008 June/July PDF

     I CO-INFECTIONS: A. Coming up: updates on hepatitis C

     I CO-INFECTIONS: B. The growing problem of insulin resistance

     I CO-INFECTIONS: C. Risk factors for insulin resistance in hep C

     I CO-INFECTIONS: D. French study finds recovery from hep c blocked by insulin resistance

     I CO-INFECTIONS: E. Dangerous liaisons: risky sex, drugs and hep C

     I CO-INFECTIONS: F. Rapid liver damage after recent HCV co-infection

     I CO-INFECTIONS: G. Some good news about HAART and liver health

     I CO-INFECTIONS: H. Unexpected liver damage—is ddI to blame?

     I CO-INFECTIONS: I. The disturbing issue of HCV re-infection

     I CO-INFECTIONS: J. Predicting recovery from hep C

TU 167 2008 April/May PDF

     I NUTRITION: A. Chromium deficiency in HIV

     I NUTRITION: B. Can chromium supplements help body shape?

     II HORMONES: A. Ovaries—hormone troubles in some HIV positive women

     III CO-INFECTIONS: A. Hepatitis C virus—some background information

     III CO-INFECTIONS: B. Liver damage occurs early in hepatitis C infection

     III CO-INFECTIONS: C. Changes to fats and sugar in the blood because of hepatitis C

TU 166 2008 March PDF

     I ANTI-HIV AGENTS: A. Introduction

     I ANTI-HIV AGENTS: B. Controversial findings on abacavir and heart attacks

     I ANTI-HIV AGENTS: C. Lopinavir and ritonavir (Kaletra) tablets get tested

     I ANTI-HIV AGENTS: D. A note about clinical trials

     I ANTI-HIV AGENTS: E. The Castle study: lopinavir vs. atazanavir

     I ANTI-HIV AGENTS: F. Is PF-232798 a possible successor to maraviroc?

     I ANTI-HIV AGENTS: G. Receptor blocker (SCH 532706) enters clinical trials

     I ANTI-HIV AGENTS: H. Vicriviroc

     II PREVENTION: A. The elusive AIDS vaccine

     II PREVENTION: B. Swiss guidelines take a troubling turn

TU 165 2008 January PDF

     I ANTI-HIV AGENTS: A. Using only lopinavir/ritonavir (Kaletra)

     I ANTI-HIV AGENTS: B. A trial of Kaletra monotherapy

     I ANTI-HIV AGENTS: C. Considering monotherapy

     I ANTI-HIV AGENTS: D. What makes a viral load blip?

     I ANTI-HIV AGENTS: E. Viral load blips linked to adherence

TU 164 September/October 2007 PDF

     I. ANTI-HIV AGENTS: A. Maraviroc approved in Canada

     I. ANTI-HIV AGENTS: B. One year results with maraviroc

     I. ANTI-HIV AGENTS: C. Maraviroc and resistance

     I. ANTI-HIV AGENTS: D. Using maraviroc in first-line therapy

     I. ANTI-HIV AGENTS: E. Another receptor blocker— INCB9471

     I. ANTI-HIV AGENTS: F. PRO 140—a receptor antibody for HIV

     I. ANTI-HIV AGENTS: G. Raltegravir (Isentress)—results after one year

     I. ANTI-HIV AGENTS: H. New drugs—hope and a degree of caution

TU 163 July/August 2007 PDF

     I ANTI-HIV AGENTS: A. Treatments for drug-resistant HIV coming

     I ANTI-HIV AGENTS: B. Darunavir shows its strength

     I ANTI-HIV AGENTS: C. Taking PEP to prevent HIV infection—results from Denmark

     II COMPLICATIONS AND SIDE EFFECTS: A. Minimizing fat loss—comparing nukes

     II COMPLICATIONS AND SIDE EFFECTS: B. Bone changes after starting HAART

     II COMPLICATIONS AND SIDE EFFECTS: C. Yoga for heart disease

     II COMPLICATIONS AND SIDE EFFECTS: D. Abacavir hypersensitivity testing results—Montreal

     III INFECTIONS: A. Sex and hepatitis C infection in Germany

     IV CANCER: A. Rise in risk for skin cancer reported

TU 162 2007 May/June PDF

     I COMPLICATIONS AND SIDE EFFECTS: A. Shifting from survival to health maintenance

     I COMPLICATIONS AND SIDE EFFECTS: B. At risk for bone breaking

     I COMPLICATIONS AND SIDE EFFECTS: C. HAART and bones—mixed messages

     I COMPLICATIONS AND SIDE EFFECTS: D. Are methadone users at risk for osteoporosis?

     I COMPLICATIONS AND SIDE EFFECTS: E. Zoledronic acid for thicker bones

     I COMPLICATIONS AND SIDE EFFECTS: F. Benefits of bone drugs appear to outweigh risks

     I COMPLICATIONS AND SIDE EFFECTS: G. Muscle mass important for maintaining bone density in women

     I COMPLICATIONS AND SIDE EFFECTS: H. Calcium and vitamin D

TU 161 2007 March/April PDF

     I ANTI-HIV AGENTS: A. Getting to know your co-receptors

     I ANTI-HIV AGENTS: B. Maraviroc—coming soon

     I ANTI-HIV AGENTS: C. Maraviroc—absorption and drug-interaction issues

     I ANTI-HIV AGENTS: D. Access to maraviroc

     II SIDE EFFECTS AND COMPLICATIONS: A. Stimulating growth hormone

     II SIDE EFFECTS AND COMPLICATIONS: B. Tesamorelin—results from Phase III

     II SIDE EFFECTS AND COMPLICATIONS: C. Clinical trials of tesamorelin in Canada

TU 160 2007 February PDF

     I ANTI-HIV AGENTS: A. New drugs, new hope, old lessons

     I ANTI-HIV AGENTS: B. Leading to lipodystrophy

     I ANTI-HIV AGENTS: C. American study finds efavirenz linked to fat wasting

     I ANTI-HIV AGENTS: D. A second study confirms fat loss issues with efavirenz

     I ANTI-HIV AGENTS: E. Efavirenz and fat wasting—what might be happening?

     I ANTI-HIV AGENTS: F. Integrase inhibitor raltegravir makes its mark

     I ANTI-HIV AGENTS: G. Raltegravir—other issues

TU 159 2007 January PDF

     I ANTI-HIV AGENTS: A. Some researchers call for early HIV therapy

     I ANTI-HIV AGENTS: B. The need for etravirine (TMC125)

     I ANTI-HIV AGENTS: C. Effectiveness of etravirine in treatment-experienced PHAs

     I ANTI-HIV AGENTS: D. Etravirine—Interactions with some medications

     I ANTI-HIV AGENTS: E. Non-nukes and the brain

     I ANTI-HIV AGENTS: F. Brain side effects not common with etravirine

     I ANTI-HIV AGENTS: G. Darunavir and some antidepressants

     I ANTI-HIV AGENTS: H. Tipranavir for treatment-experienced PHAs

     I ANTI-HIV AGENTS: I. Starting therapy with saquinavir

     I ANTI-HIV AGENTS: J. Promising results from a saquinavir study

TU 158 2006 October/November PDF

     I ANTI-HIV AGENTS: A. Integrase inhibitors come of age

     I ANTI-HIV AGENTS: B. Merck’s integrase inhibitor—short-term safety

     I ANTI-HIV AGENTS: C. Some drug interactions with Merck’s integrase inhibitor

Previous Next


	See also

	CATIE-News What's New? CATIE Publications

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner who is knowledgeable about HIV-related illness and the treatments in question. MORE

Privacy | Permission to reproduce | Funders

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.